CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84,77
Prezzo · Ago 19, 2026
Fondamentali al Ago 3, 2026
Intervallo 52 sett.
$29–$85
100% of range
Rating Analisti
HOLD
21 analysts
Prezzo Obiettivo
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
Margine di Profitto Netto
-6046.2%
Informazioni su Crinetics Pharmaceuticals, Inc. - Common Stock Panoramica della società da Wikipedia
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Leggi di più
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
CRNX Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$84.77
Capitalizzazione di Mercato
$8.10B
P/E (TTM)
-17.1
EPS (TTM)
$-4.95
Ricavi (TTM)
$8M
Rendimento div.
—
ROE
-43.0%
D/E Debito/Patrimonio
—
Intervallo 52 sett.
$29 – $85
CRNX Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Configure
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi e Utile Netto
$8M
2016-12-31
→
2025-12-31
EPS
$-4.95
2020-12-31
→
2025-12-31
Flusso di cassa libero
$-384M
2018-12-31
→
2025-12-31
Margini
-6046.2%
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Metrica
Tendenza 5 anni
CRNX
Mediana dei peer
P/E (TTM)
-17.1
47.9
P/S (TTM)
1052.7
16.2
P/B
8.2
9.3
Price / FCF (Prezzo / FCF)
-21.1
—
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Metrica
Tendenza 5 anni
CRNX
Mediana dei peer
Operating Margin (Margine Operativo)
-6714.8%
—
Net Profit Margin (Margine di Profitto Netto)
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Metrica
Tendenza 5 anni
CRNX
Mediana dei peer
Current Ratio (Rapporto corrente)
12.3
2.7
Quick Ratio
12.1
—
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Metrica
Tendenza 5 anni
CRNX
Mediana dei peer
Revenue YoY (Ricavi YoY)
640.7%
—
Revenue CAGR 3Y (CAGR Ricavi 3Y)
17.6%
—
Revenue CAGR 5Y (CAGR Ricavi 5Y)
155.3%
—
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Metrica
Tendenza 5 anni
CRNX
Mediana dei peer
CRNX Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
MANTIENI
21 analisti
- Acquisto forte 3 14,3%
- Compra 4 19,0%
- Mantieni 14 66,7%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
10 analisti · 2026-08-13
Mediana
$85.00
Media
$85.50
← Sotto tutti i target
$84.77
Basso
$85.00
Alto
$90.00
Target mediano
$85.00
+0,3%
Target medio
$85.50
+0,9%
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-0.01%
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $-1.14 | $-1.23 | 0.09% |
| 31 Marzo 2026 | $-1.23 | $-1.26 | 0.03% |
| 31 Dicembre 2025 | $-1.29 | $-1.39 | 0.10% |
| 30 Settembre 2025 | $-1.38 | $-1.28 | -0.10% |
| 30 Giugno 2025 | $-1.23 | $-1.12 | -0.11% |
| 31 Marzo 2025 | $-1.04 | $-0.96 | -0.08% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
Stato Patrimoniale 24
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
Flusso di cassa 13
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
Redditività 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
Liquidità e Solvibilità 2
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
Tassi di Crescita 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
Valutazione (TTM) 10
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
Conto Economico 15
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
Stato Patrimoniale 23
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
Flusso di cassa 10
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
Redditività 6
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
Liquidità e Solvibilità 2
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 10
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $8M | $1M | $4M | $5M | $1M |
| Margine Operativo % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| Utile netto | $-465M | $-298M | $-215M | $-164M | $-108M |
| EPS Diluito | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Rapporto corrente | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $-384M | $-230M | $-171M | $-117M | $-89M |
Ultime notizie Notizie recenti che menzionano questa società
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
📊
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 286 filer · $3.2B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 63 (+17 vs trimestre precedente) | 30 (-14 vs trimestre precedente) | 95 (-17 vs trimestre precedente) | 63 (+3 vs trimestre precedente) | +21.6M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| FMR LLC | $486.250.673 | 12.994.406 | 15,13% | Azioni |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336.372.047 | 8.989.098 | 10,46% | Azioni |
| Driehaus Capital Management LLC | $241.866.078 | 6.463.551 | 7,52% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $237.002.526 | 6.333.579 | 7,37% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180.836.416 | 4.832.614 | 5,63% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $177.567.704 | 4.745.262 | 5,52% | Azioni |
| STATE STREET CORP | $100.635.477 | 2.689.350 | 3,13% | Azioni |
| Bellevue Group AG | $98.040.400 | 2.620.000 | 3,05% | Azioni |
| BAKER BROS. ADVISORS LP | $87.991.820 | 2.351.465 | 2,74% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $87.542.675 | 2.338.905 | 2,72% | Azioni |
| Polar Capital Holdings Plc | $85.108.460 | 2.274.411 | 2,65% | Azioni |
| Pictet Asset Management Holding SA | $77.572.984 | 2.075.375 | 2,41% | Azioni |
| Siren, L.L.C. | $53.165.887 | 1.420.788 | 1,65% | Azioni |
| First Light Asset Management, LLC | $50.923.606 | 1.360.866 | 1,58% | Azioni |
| NOVO HOLDINGS A/S | $49.394.400 | 1.320.000 | 1,54% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $47.245.129 | 1.262.562 | 1,47% | Azioni |
| ADAR1 Capital Management, LLC | $45.730.234 | 1.222.080 | 1,42% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $44.555.208 | 1.190.679 | 1,39% | Azioni |
| MONTANOVA CAPITAL, LLC | $44.390.560 | 1.186.279 | 1,38% | Azioni |
| ORBIMED ADVISORS LLC | $37.382.580 | 999.000 | 1,16% | Azioni |
| Hood River Capital Management LLC | $36.259.830 | 968.996 | 1,13% | Azioni |
| GOLDMAN SACHS GROUP INC | $34.657.132 | 926.166 | 1,08% | Azioni |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32.841.401 | 877.643 | 1,02% | Azioni |
| Aberdeen Group plc | $30.699.181 | 820.395 | 0,95% | Azioni |
| Candriam S.C.A. | $30.618.690 | 819.032 | 0,95% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $28.230.995 | 754.436 | 0,88% | Azioni |
| Fisher Asset Management, LLC | $27.748.912 | 741.553 | 0,86% | Azioni |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17.709.036 | 479.400 | 0,55% | Azioni |
| AMERIPRISE FINANCIAL INC | $17.451.149 | 466.356 | 0,54% | Azioni |
| Impax Asset Management Group plc | $16.277.700 | 435.000 | 0,51% | Azioni |
| Prosight Management, LP | $14.020.002 | 374.666 | 0,44% | Azioni |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13.991.714 | 373.910 | 0,44% | Azioni |
| KENNEDY CAPITAL MANAGEMENT LLC | $13.685.018 | 365.714 | 0,43% | Azioni |
| BRAUN STACEY ASSOCIATES INC | $13.027.511 | 348.143 | 0,41% | Azioni |
| Fiera Capital Corp | $12.395.263 | 331.247 | 0,39% | Azioni |
| BANK OF AMERICA CORP /DE/ | $11.271.877 | 301.226 | 0,35% | Azioni |
| Defilade Capital Management, L.P. | $8.959.845 | 239.440 | 0,28% | Azioni |
| SEB Asset Management AB | $8.003.786 | 213.891 | 0,25% | Azioni |
| Foresite Capital Management VI LLC | $7.933.414 | 212.010 | 0,25% | Azioni |
| RICE HALL JAMES & ASSOCIATES, LLC | $7.346.220 | 196.318 | 0,23% | Azioni |
| TD Asset Management Inc | $7.152.534 | 191.142 | 0,22% | Azioni |
| Swiss National Bank | $6.877.796 | 183.800 | 0,21% | Azioni |
| SEGALL BRYANT & HAMILL, LLC | $6.855.307 | 183.199 | 0,21% | Azioni |
| BlackRock, Inc. | $6.781.290 | 181.221 | 0,21% | Azioni |
| JENNISON ASSOCIATES LLC | $6.056.839 | 161.861 | 0,19% | Azioni |
| New Leaf Venture Partners, L.L.C. | $5.872.650 | 141.000 | 0,18% | Azioni |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5.865.136 | 156.738 | 0,18% | Azioni |
| Foresite Capital Management IV, LLC | $5.613.000 | 150.000 | 0,17% | Azioni |
| Bank of New York Mellon Corp | $5.581.754 | 149.165 | 0,17% | Azioni |
| NEW YORK STATE COMMON RETIREMENT FUND | $5.508.898 | 147.218 | 0,17% | Azioni |
| ENVESTNET ASSET MANAGEMENT INC | $5.471.384 | 146.216 | 0,17% | Azioni |
| Moody Aldrich Partners LLC | $5.466.201 | 146.077 | 0,17% | Azioni |
| Ishara Investments LP | $5.369.770 | 143.500 | 0,17% | Azioni |
| CITADEL ADVISORS LLC | $5.176.271 | 138.329 | 0,16% | Azioni |
| RHUMBLINE ADVISERS | $4.861.141 | 129.908 | 0,15% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $4.782.618 | 131.680 | 0,15% | Azioni |
| GordonMD Global Investments LP | $4.751.779 | 126.985 | 0,15% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4.712.974 | 125.948 | 0,15% | Azioni |
| JANUS HENDERSON GROUP PLC | $4.700.428 | 129.392 | 0,15% | Azioni |
| Cormorant Asset Management, LP | $4.677.500 | 125.000 | 0,15% | Azioni |
| SECTOR GAMMA AS | $4.289.380 | 114.628 | 0,13% | Azioni |
| XTX Topco Ltd | $4.164.547 | 111.292 | 0,13% | Azioni |
| ALPS ADVISORS INC | $3.981.825 | 106.409 | 0,12% | Azioni |
| FEDERATED HERMES, INC. | $3.957.390 | 105.756 | 0,12% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3.834.048 | 105.563 | 0,12% | Azioni |
| Nuveen Asset Management, LLC | $3.760.151 | 73.541 | 0,12% | Azioni |
| Burkehill Global Management, LP | $3.742.000 | 100.000 | 0,12% | Azioni |
| Nuveen, LLC | $3.619.262 | 96.720 | 0,11% | Azioni |
| VICTORY CAPITAL MANAGEMENT INC | $3.484.251 | 93.112 | 0,11% | Azioni |
| MORGAN STANLEY | $3.320.829 | 88.744 | 0,10% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $3.266.729 | 87.299 | 0,10% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $3.254.754 | 86.979 | 0,10% | Azioni |
| AWM Investment Company, Inc. | $3.180.700 | 85.000 | 0,10% | Azioni |
| Odyssean, LLC | $3.160.344 | 84.456 | 0,10% | Azioni |
| Affinity Asset Advisors, LLC | $2.806.500 | 75.000 | 0,09% | Azioni |
| ALGERT GLOBAL LLC | $2.714.147 | 72.532 | 0,08% | Azioni |
| ExodusPoint Capital Management, LP | $2.652.404 | 70.882 | 0,08% | Azioni |
| Ensign Peak Advisors, Inc | $2.507.290 | 67.004 | 0,08% | Azioni |
| BARCLAYS PLC | $2.466.127 | 65.904 | 0,08% | Azioni |
| FIRST TRUST ADVISORS LP | $2.370.631 | 63.352 | 0,07% | Azioni |
| Man Group plc | $2.284.229 | 61.043 | 0,07% | Azioni |
| MetLife Investment Management, LLC | $2.258.709 | 60.361 | 0,07% | Azioni |
| CITIGROUP INC | $2.255.229 | 60.268 | 0,07% | Azioni |
| Longaeva Partners L.P. | $2.184.879 | 58.388 | 0,07% | Azioni |
| Swedbank AB | $2.155.392 | 57.600 | 0,07% | Azioni |
| STATE OF WISCONSIN INVESTMENT BOARD | $2.068.016 | 55.265 | 0,06% | Azioni |
| Jump Financial, LLC | $1.923.388 | 51.400 | 0,06% | Azioni |
| Lighthouse Investment Partners, LLC | $1.871.000 | 50.000 | 0,06% | Azioni |
| Vestmark Advisory Solutions, Inc. | $1.823.252 | 48.724 | 0,06% | Azioni |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1.787.254 | 47.762 | 0,06% | Azioni |
| VANGUARD GROUP INC | $1.774.626 | 38.123 | 0,06% | Azioni |
| Point72 Asset Management, L.P. | $1.735.577 | 46.381 | 0,05% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $1.696.398 | 45.334 | 0,05% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $1.606.254 | 42.925 | 0,05% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.549.188 | 41.400 | 0,05% | Opzione Call |
| Invesco Ltd. | $1.545.446 | 41.300 | 0,05% | Azioni |
| Vanguard Global Advisers, LLC | $1.485.986 | 39.711 | 0,05% | Azioni |
| HighMark Wealth Management LLC | $1.444.224 | 38.595 | 0,04% | Azioni |
| OAK RIDGE INVESTMENTS LLC | $1.405.046 | 37.548 | 0,04% | Azioni |
| Orion Porfolio Solutions, LLC | $1.404.234 | 37.526 | 0,04% | Azioni |
Insider aziendali 20 insider · 9 dirigenti · 10 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 10 Marzo 2025 A | 52.000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 26 Settembre 2024 M | 111.092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 19 Marzo 2025 S | 87.491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 12 Giugno 2025 M | 99.713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 19 Marzo 2025 S | 72.233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 10 Gennaio 2025 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 05 Luglio 2024 M | 29.259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 17 Ottobre 2023 M | 43.210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 28 Febbraio 2022 A | 176.995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Direttore | 02 Luglio 2026 S | 19.225 | 0 | 1 | $-120.000 |
| Caren Deardorf | Direttore | 18 Giugno 2026 A | 22.225 | 0 | 0 | $0 |
| Weston Nichols | Direttore | 18 Giugno 2026 A | 22.225 | 0 | 0 | $0 |
| Stephanie Okey | Direttore | 18 Giugno 2026 A | 12.325 | 0 | 2 | $-246.143 |
| Matthew K Fust | Direttore | 18 Giugno 2026 A | 28.761 | 0 | 0 | $0 |
| Camille L Bedrosian | Direttore | 18 Giugno 2026 A | 22.225 | 0 | 0 | $0 |
| Wendell Wierenga | Direttore | 18 Giugno 2026 A | 122.071 | 0 | 0 | $0 |
| Wendall Wierenga | Direttore | 11 Giugno 2025 A | 116.146 | 0 | 0 | $0 |
| Stephen W Kaldor | Direttore | 19 Giugno 2020 A | — | 0 | 0 | $0 |
| Jack Nielsen | Direttore | 21 Giugno 2019 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 07 Agosto 2026 M | 424.706 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 1 partecipazione
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 depositi | 01 Marzo 2024 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 55 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2,37% | 107.892 NS | 31 Maggio 2026 | N-PORT |
| IHE · iShares Trust | 1,95% | 376.636 SH | 08 Agosto 2026 | Giornaliero |
| FMED · Fidelity Covington Trust | 1,65% | 19.000 NS | 31 Maggio 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,40% | 4.666 NS | 30 Aprile 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,23% | 18.743 NS | 30 Aprile 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,75% | 11.043 NS | 31 Maggio 2026 | N-PORT |
| IBB · iShares Trust | 0,63% | 718.323 SH | 08 Agosto 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,60% | 5.737 SH | 08 Agosto 2026 | Giornaliero |
| IWO · iShares Trust | 0,54% | 940.202 SH | 08 Agosto 2026 | Giornaliero |
| NUSC · Nushares ETF Trust | 0,28% | 93.045 NS | 30 Aprile 2026 | N-PORT |
| ISCG · iShares Trust | 0,27% | 32.694 SH | 08 Agosto 2026 | Giornaliero |
| IWM · iShares Trust | 0,27% | 2.625.192 SH | 08 Agosto 2026 | Giornaliero |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,23% | 110.770 SH | 08 Agosto 2026 | Giornaliero |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,20% | 38.553 NS | 30 Aprile 2026 | N-PORT |
| BIB · ProShares Trust | 0,19% | 3.872 NS | 31 Maggio 2026 | N-PORT |
| ESML · iShares Trust | 0,16% | 55.438 SH | 08 Agosto 2026 | Giornaliero |
| BKSE · BNY Mellon ETF Trust | 0,15% | 3.142 NS | 30 Aprile 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,15% | 51.135 SH | 08 Agosto 2026 | Giornaliero |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,14% | 18.879 NS | 30 Aprile 2026 | N-PORT |
| ISCB · iShares Trust | 0,13% | 4.625 SH | 08 Agosto 2026 | Giornaliero |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,12% | 596.648 SH | 08 Agosto 2026 | Giornaliero |
| RSSL · Global X Funds | 0,12% | 42.391 NS | 30 Aprile 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,11% | 1.399.667 SH | 08 Agosto 2026 | Giornaliero |
| FFSM · FIDELITY COVINGTON TRUST | 0,10% | 31.759 NS | 30 Aprile 2026 | N-PORT |
| ITWO · ProShares Trust | 0,09% | 4.601 NS | 31 Maggio 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,09% | 2.909 SH | 08 Agosto 2026 | Giornaliero |
| SCHA · SCHWAB STRATEGIC TRUST | 0,08% | 492.431 NS | 31 Maggio 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 24.991 NS | 30 Aprile 2026 | N-PORT |
| WSML · iShares Trust | 0,07% | 5.742 SH | 08 Agosto 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,06% | 41.183 NS | 30 Aprile 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 196.549 NS | 30 Aprile 2026 | N-PORT |
| UWM · ProShares Trust | 0,05% | 3.599 NS | 31 Maggio 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,05% | 2.419.186 SH | 08 Agosto 2026 | Giornaliero |
| VHT · VANGUARD WORLD FUND | 0,05% | 275.155 SH | 08 Agosto 2026 | Giornaliero |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,04% | 5.196 NS | 30 Aprile 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1.210.574 SH | 08 Agosto 2026 | Giornaliero |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,04% | 112 NS | 31 Maggio 2026 | N-PORT |
| URTY · ProShares Trust | 0,04% | 3.643 NS | 31 Maggio 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 5.689 NS | 31 Maggio 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,02% | 3.773 NS | 31 Maggio 2026 | N-PORT |
| HDG · ProShares Trust | 0,02% | 91 NS | 31 Maggio 2026 | N-PORT |
| ITOT · iShares Trust | 0,01% | 146.419 SH | 08 Agosto 2026 | Giornaliero |
| IWV · iShares Trust | 0,01% | 27.043 SH | 08 Agosto 2026 | Giornaliero |
| DFAC · Dimensional ETF Trust | 0,01% | 125.853 NS | 30 Aprile 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 3.342.704 SH | 08 Agosto 2026 | Giornaliero |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 8.345 SH | 08 Agosto 2026 | Giornaliero |
| ESGV · VANGUARD WORLD FUND | 0,01% | 22.843 SH | 08 Agosto 2026 | Giornaliero |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 28.694 NS | 31 Maggio 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 5.863 NS | 30 Aprile 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 3.388 NS | 30 Aprile 2026 | N-PORT |